Loading
A phase 1/2 trial of NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers. in uveal melanoma, run by Novelwise Pharmaceutical Corporation, now recruiting.
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma is a phase 1/2 interventional study registered as NCT07136181 by Novelwise Pharmaceutical Corporation, with 36 participants planned, started 2025-11-20 and due to reach its primary completion in 2028-03-28. Interventions recorded: NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers..
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/